Word count: 729

References: 5

Real-time evaluation of gastrointestinal pH and transit time in patients with essential hypertension

Running title: Colonic pH and hypertension

Evany Dinakis[1,2], Liang Xie[1,3], Dakota Rhys-Jones[4], Dovile Anderson[5], CK Yao[4], Daniel So[4], Darren J. Creek[6], Peter R. Gibson[4], Jane Muir[4], Francine Z. Marques[1,2,7*]

[1]Hypertension Research Laboratory, Department of Pharmacology, Biomedical Discovery Institute, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton VIC 3800, Australia; [2]Victorian Heart Hospital, Monash University, Clayton VIC, 3168, Australia; [3]Precision Medicine Translational Research Programme, Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; [4]Department of Gastroenterology, Central Clinical School, Monash University, Melbourne, 3000, Victoria, Australia; [5]Monash Proteomics and Metabolomics Facility, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia; [6]Monash Biomedical Imaging, Monash University, Clayton, VIC 3168, Australia; [7]Baker Heart and Diabetes Institute, Melbourne, VIC 3000, Australia.

*__Corresponding author__: Prof Francine Marques, Hypertension Research Laboratory, Victorian Heart Institute, Level 2, Victorian Heart Hospital, 631 Blackburn Road, Clayton, VIC 3168 Monash University, Melbourne, Australia, Phone: +61-03-9905 6958. E-mail: francine.marques@monash.edu

Abstract

Dietary fibre fermentation produces short-chain fatty acids (SCFAs) that lower colonic luminal pH, influencing host responses that contribute to blood pressure (BP) regulation. Fibre intake also alters gastrointestinal transit time, which has been linked to hypertension prevalence. Here, we aimed to determine the gastrointestinal pH and transit time in patients with hypertension. Using the SmartPill™ Motility Testing System, we assessed gastrointestinal pH and transit time in 55 participants with normal and elevated BP measured by ambulatory BP monitoring. Participants with hypertension exhibited a higher colonic minimum pH than those with normal BP. This difference was not explained by antihypertensive medication use or BP control, gastrointestinal transit time, nutrient intake or circulating SCFA levels. These findings suggest a potential relationship between colonic pH profiles and BP regulation, underscoring the need for future research into gut pH dynamics as emerging contributors to cardiovascular disease risk and progression.

Hypertension management has traditionally relied on pharmacological approaches; however, dietary strategies remain the first-line recommendation as adjunctive or preventive measures.[1] Among these, dietary fibre, particularly fermentable fibre, has emerged as a strong candidate.[1] Fermentable fibres are a subclass of non-digestible carbohydrates that resist digestion in the small intestine and undergo microbial fermentation in the large intestine, subsequently leading to the production of acidic by-products known as short-chain fatty acids (SCFAs), particularly acetate, butyrate and propionate.[1] This process is most pronounced in the proximal colon, particularly the ascending and transverse regions, where microbial density and fermentable fibre availability are highest.[2] These acidic microbial metabolites lower colonic luminal pH, which in turn modulates host immune responses,[3] recognised as a key contributing factor to blood pressure (BP) homeostasis. Importantly, a more acidic colonic milieu leads to the activation of pH-sensing G protein-coupled receptors (GPCRs) that regulate BP in mice.[1,3] Dietary fibre also influences gastrointestinal transit time,[2] the duration ingested substances take to move through the digestive tract,[4] which is in turn associated with the prevalence of hypertension.[1]

Here, we aimed to determine the gastrointestinal pH and transit time in patients with hypertension. Wireless monitoring technologies enable real-time evaluation of gastrointestinal physicochemical profiles in healthy humans,[4] overcoming limitations of *in vivo* intestinal measurements. Leveraging this, we employed the SmartPill motility testing system, an accurate, non-invasive motility and pH diagnostic pill, to investigate pH dynamics and their potential association with BP regulation in 55 participants with normal and elevated BP measured by ambulatory BP monitoring (Figure A). Consistent with animal findings,[3] hypertensive participants had higher colonic minimum pH than normotensive participants (mean±SEM, normotensives: 5.03±0.081 vs hypertensives: 5.22±0.053, P=0.024). This reflects the pH in the proximal colon, where fibre fermentation takes place.[1,4] This difference

in pH may activate pH-sensing receptors, such as GPR65, which regulate BP via reducing pro-inflammatory cytokine production by $CD8^+$ T cells.[3] In sensitivity analyses, colonic minimum pH did not differ significantly between treated (i.e., on prescribed BP-lowering medication) and untreated participants (Figure C), suggesting that antihypertensive medication use is not associated with alterations in colonic pH. Of the 16 participants treated, only 6 (37.5%) had controlled BP; however, there was no difference in colonic minimum pH between controlled and uncontrolled hypertensive groups (Figure C).

As fermentable fibre is progressively depleted along the colon, SCFA production declines while pH increases.[2] However, we found no difference between groups in colonic median and maximum pH (Figure B), which is representative of the distal colon.[4] Moreover, no significant differences between normotensive and hypertensive participants were observed in transit time across the whole gastrointestinal tract, the small intestine, the colon, or the combined small and large intestine (Figure D).

We then investigated nutrient intake between normotensive and hypertensive participants, as food may influence microbial fermentation and colonic pH. Although protein and sugar intake were retained in the final regression model, neither variable was statistically significant (Figure E). Epidemiological evidence supports an inverse association between dietary fibre intake and BP levels, with meta-analyses indicating that incremental increases in fibre consumption lead to clinically meaningful reductions in BP.[5] We found that hypertensive participants had similar dietary fibre intake compared to normotensives (P=0.38, Figure E); however, the average consumption in both groups remained under the recommended intake of 25–30 g/day depending on sex (normotensives vs hypertensives; 25.5±7.6 vs 26.1±10.0 g/day, data not shown).[5] These findings are mirrored in the circulating SCFA profiles of normotensive and hypertensive participants, whereby differences in acetic,

propionic, butanoic and valeric acid, as well as two branched isomers (iso-valeric and -butanoic) were not significantly different (Figure F).

We acknowledge that the small cohort size is a limitation of this study; however, this is the most comprehensive characterisation of human colonic intraluminal pH and transit time using a unique *in vivo* motility testing system that is no longer commercially available. Thus, this cohort provides a rare opportunity to investigate the relationship between BP regulation and physicochemical factors of the gut, thereby advancing our understanding of the gut-cardiovascular axis in humans.

In conclusion, our data suggest that whilst colonic minimum pH is higher in hypertensive participants, this was not mediated through anti-hypertensive medication intake, transit time, or nutrient intake. Nonetheless, these findings offer novel insight into the potential relationship between colonic pH profiles and BP regulation, highlighting the need for future research to investigate pH-related gut parameters as emerging contributors to cardiovascular disease risk and progression.

References

1. O'Donnell JA, Zheng T, Meric G, Marques FZ. The gut microbiome and hypertension. *Nat Rev Nephrol*. 2023;19:153-167. doi: 10.1038/s41581-022-00654-0
2. Procházková N, Falony G, Dragsted LO, Licht TR, Raes J, Roager HM. Advancing human gut microbiota research by considering gut transit time. *Gut*. 2023;72:180-191. doi: 10.1136/gutjnl-2022-328166
3. Xie L, Muralitharan RR, Dinakis E, Antonacci S, Leung KC, McArdle Z, Mirabito Colafella K, Nakai M, Paterson M, Peh A, et al. Dietary fibre controls blood pressure and cardiovascular risk by lowering large intestinal pH and activating the proton-sensing receptor GPR65. *bioRxiv*. 2025:2022.2011.2017.516695. doi: 10.1101/2022.11.17.516695
4. Fallingborg J, Christensen L, Ingeman□Nielsen M, Jacobsen B, Abildgaard K, Rasmussen H. pH□profile and regional transit times of the normal gut measured by a radiotelemetry device. *Alimentary pharmacology & therapeutics*. 1989;3:605-614.
5. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *The Lancet*. 2019;393:434-445. doi: 10.1016/S0140-6736(18)31809-9

Figure legend

A, Out of 91 expressions of interest, 55 participants completed the pH of Intestines and Blood-pressure Regulation (pHibre) clinical trial study. GI, gastrointestine; COVID, SARS-CoV-2 infection; BMI, body mass index; BP, blood pressure. The study was approved by the Monash University Human Research Ethics Committee (Study ID: 23336) and conducted in accordance with the Declaration of Helsinki. All participants provided written consent. The study was registered under the Australian New Zealand Clinical Trials Registry (ACTRN12620000284965). Participants with or without hypertension were recruited for this study and were classified as normotensive (n=15) or hypertensive (n=40) using 24-hour ambulatory BP monitoring (hypertension threshold: day or night systolic and/or diastolic BP ≥135/85 mmHg or 120/75 mmHg, respectively). Participants completed a three-day food diary before the visit, analysed using FoodWorks 10 (Xyris, Queensland) to calculate average nutrient intake. Fasting participants swallowed a SmartPill™ capsule, which was monitored by a SmartPill™ Motility Testing System (Medtronic) to measure intraluminal pH and transit time in real time as it travelled through the gastrointestinal tract. Short-chain fatty acids (SCFAs) were quantified in fasting plasma using liquid chromatography-mass spectrometry. Binary logistic regression modelling revealed age and sex as significant predictors of blood pressure status (i.e., normotensives vs hypertensives), while BMI was not (P=0.24). **B,** Colonic minimum, median and maximum pH of normotensive (n=15) and hypertensive (n=40) participants. **C,** Colonic minimum pH of untreated (n=24) and treated (n=16) hypertensive participants, and treated hypertensive participants with uncontrolled (n=10) and controlled (n=6) BP. **D,** Average whole gastrointestinal, small bowel, colonic and combined small and large bowel transit time of normotensive (n=15) and hypertensive (n=40) participants. **E,** Horizontal bar plot showing the $-\log_{10}$(P-value) of nutrient intake between normotensive (n=15) and hypertensive (n=40) participants. **F,** Plasma short-chain fatty acid (SCFA) concentrations, including acetic, propionic, butanoic, valeric, isovaleric and isobutanoic acid of normotensive (n=15) and hypertensive (n=40) participants. Each data point represents an individual participant. All data represented as mean ± SEM; P-values from stepwise binary logistic regression analysis that included age, sex and BMI as independent variables, as well-known risk factors for hypertension (criteria of step-wise F-entry probability: 0.15, removal: 0.20). P<0.05 was considered statistically significant. Data was collected and experiments were performed blindly.


A
91 expressions of interest
Phone screening:
8 x GI issues
4 x Diabetes
3 x COVID-19
3 x Dietary requirement
2 x Antibiotic or probiotic intake
2 x Age out of range
2 x BMI out of range
1 x Pregnancy
15 x Other
60 screened
1 x Probiotic intake
1 x Diabetes
1 x Swallowing issue
1 x Other commitments
56 completed
1 x Incorrect protocol
15 Normotensives
40 Hypertensives (including 16 treated; 6 with controlled BP)
Blood Pressure (BP) Monitoring (n=55)
24-hour ambulatory BP measurements (ABPM)
24-hour Day BP
24-hour Night BP
Overall BP
Systolic, diastolic
SmartPill Motility Testing System (n=55)
Intraluminal Colonic pH
Minimum
Median
Maximum
Transit time (TT)
Small bowel (SB)
Colonic (C)
Whole gut (WG)
Dietary Habits (n=54)
3-day food diary
2 weekdays
1 weekend day
Food composition software FoodWorks 10
Nutrient intake
Whole Blood (n=54)
Plasma Isolation
Short-chain fatty acid (SCFA) quantification
Liquid Chromatography-Mass Spectrometry (LC-MS)
Propionic
Isovaleric
Isobutanoic
Acetic
Butanoic
Valeric
B
Colonic pH
P=0.024
P=0.212
P=0.881
Minimum
Median
Maximum
C
Colonic minimum pH
P=0.779
P=0.468
Untreated hypertensives
Treated hypertensives
Uncontrolled BP
Controlled BP
Treated hypertensives
D
Average transit time (h)
P=0.187
P=0.951
P=0.210
P=0.206
Whole gut
Small bowel
Colonic
Small and large bowel
Normotensives
Hypertensives
E
Nutrient intake (g)
Protein
Sugars
Saturated fat
Carbohydrates
Dietary fibre
Total fat
Starch
Polyunsaturated fat
Monounsaturated fat
0.00
0.25
0.50
0.75
1.00
$-\log_{10}(P)$
F
Plasma SCFA concentration
P=0.615
P=0.404
P=0.191
P=0.331
P=0.133
P=0.304
Acetic acid (µg/mL)
Propionic acid (ng/mL)
Butanoic acid (ng/mL)
Valeric acid (ng/mL)
Isovaleric acid (ng/mL)
Isobutanoic acid (ng/mL)